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Pasteurella haemolytica serotype 1 is the bacterium most commonly associated with bovine shipping fever. The
presence of antibodies against P. haemolytica outer membrane proteins (OMPs) correlates statistically with
resistance to experimental P. haemolytica challenge in cattle. Until now, specific P. haemolytica OMPs which
elicit antibodies that function in host defense mechanisms have not been identified. In this study, we have
cloned and sequenced the gene encoding one such protein, PlpE. Analysis of the deduced amino acid sequence
revealed that PlpE is a lipoprotein and that it is similar to an Actinobacillus pleuropneumoniae lipoprotein,
OmlA. Affinity-purified, anti-PlpE antibodies recognize a protein in all serotypes of P. haemolytica except
serotype 11. We found that intact P. haemolytica and recombinant E. coli expressing PlpE are capable of
absorbing anti-PlpE antibodies from bovine immune serum, indicating that PlpE is surface exposed in P.
haemolytica and assumes a similar surface-exposed conformation in E. coli. In complement-mediated killing
assays, we observed a significant reduction in killing of P. haemolytica when bovine immune serum that was
depleted of anti-PlpE antibodies was used as the source of antibody. Our data suggest that PlpE is surface
exposed and immunogenic in cattle and that antibodies against PlpE contribute to host defense against P.
haemolytica.
Pasteurella haemolytica serotype 1 (S1) is the organism most
commonly associated with shipping fever, a disease of beef
cattle characterized by fibrinous pleuropneumonia (reviewed
in references 9 and 15). The disease is of significant economic
importance to the beef industry in the United States, account-
ing for annual losses approaching 1 billion dollars (18). Ship-
ping fever pneumonia is precipitated by stress-inducing condi-
tions such as shipping, viral infections, inhalation of diesel
fumes, overcrowding, and weaning (9, 15). P. haemolytica S1
resides in small numbers in the upper respiratory tracts of
cattle, and the tonsil has been shown to be a reservoir (16, 46).
Cells proliferate under stressful conditions and are aerosolized
in large numbers into lung alveoli, where they cause the disease
(16).
Numerous surface and secreted molecules of P. haemolytica
S1 have been studied to evaluate their roles in immunity to P.
haemolytica infection (reviewed in reference 6). A secreted
cytolytic toxin, leukotoxin (Lkt) (44), is a significant P. haemo-
lytica virulence factor. In one study, a vaccine consisting of
recombinant Lkt (rLkt) did not provide protection against
experimental P. haemolytica challenge (11). However, inclu-
sion of that rLkt in a commercial vaccine resulted in enhanced
resistance to challenge (11). Those results are in agreement
with data from a prior study (45), which suggested that anti-
bodies against Lkt and surface antigens are necessary for pro-
tective immunity to P. haemolytica.
The P. haemolytica surface antigens likely to be most impor-
tant in contributing to protective immunity are outer mem-
brane proteins (OMPs). Vaccination of cattle with an OMP-
enriched fraction of P. haemolytica cell envelopes significantly
reduces lung damage following experimental challenge with a
P. haemolytica strain of the homologous serotype (29). Bovine
antibody responses to proteins present in P. haemolytica sur-
face extracts correlate statistically with resistance to pneumo-
nia (10, 47). Our group and others have analyzed the bovine
antibody response to PomA, a protein belonging to the OmpA
family (28), to a 94-kDa P. haemolytica OMP (34), and to
several membrane lipoproteins (12–14, 37). These studies sug-
gest a role for outer membrane antigens in eliciting protective
immunity. However, the capacity for P. haemolytica OMP-
specific antibodies to function in host defense mechanisms
remains uncharacterized. For the development of more-effec-
tive vaccines, it will be important to characterize individual
OMPs and identify those that elicit host antibodies which en-
hance resistance to P. haemolytica infection.
Complement-mediated lysis is an important host defense
mechanism against microbial infection and is believed to play
a role in controlling P. haemolytica pneumonia. Serum com-
plement concentrations were found to be lower in stressed
cattle after transport to a feedlot (40). Lower complement
concentrations were associated with higher morbidity in the
feedlot, and morbid calves had significantly lower complement
levels than did healthy calves in the same feedlots (40). These
data suggest that a decrease in serum complement levels might
facilitate P. haemolytica infection. However, complement-me-
diated killing of P. haemolytica requires sensitization with an-
tibodies (27). Antibodies against surface-exposed epitopes of
OMPs are likely to play an important role in complement-
mediated lysis of P. haemolytica.
Cattle that are resistant to P. haemolytica-induced pneumo-
nia develop antibodies to a surface-exposed, ;45-kDa OMP
(36). The purpose of this study was to determine, through
genetic cloning and DNA sequencing, the specific identity of
the immunogenic 45-kDa protein and to evaluate the contri-
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bution of antibodies against this protein to complement-medi-
ated killing of P. haemolytica. We found that the 45-kDa pro-
tein is a lipoprotein, designated PlpE, and that antibodies
against PlpE, present in bovine immune sera, contribute to
complement-mediated killing of P. haemolytica.
MATERIALS AND METHODS
Bacteria, bacteriophage, culture media, and genomic library. P. haemolytica
(89010807N) S1 was grown in BHI broth or on BHI agar (Difco Laboratories,
Detroit, Mich.) as previously described (32). Escherichia coli BB4 and XL1-Blue
and bacteriophages lZAPII and R408 were supplied with a P. haemolytica
genomic DNA library (Clontech Laboratories, Palo Alto, Calif.) (37) and were
grown according to the manufacturer’s instructions. Recombinant E. coli strains
were grown in the presence of ampicillin (50 mg/ml).
Bovine immune sera and purification of antibodies. Two bovine immune sera
were used, one from a calf hyperimmunized with live P. haemolytica (25) and one
from a calf that was vaccinated with P. haemolytica OMPs and was resistant to
experimental P. haemolytica challenge (7). Briefly, the OMP-vaccinated calf was
vaccinated subcutaneously on day 0 and day 21 with P. haemolytica S1 OMPs (2
mg in 1 ml of phosphate buffered saline [PBS] and 1 ml of an aluminum
hydroxide-DDA-bromide adjuvant which has been described elsewhere in more
detail [8]). On day 36, the calf was experimentally challenged transthoracically
with 5 ml of a mixture containing 109 CFU of P. haemolytica S1/ml in each caudal
lung lobe. Lung damage was evaluated upon necropsy 4 days after challenge, by
using a previously described lung lesion score system (35). The serum used in this
experiment was collected on the day of experimental challenge.
Bovine sera usually contain antibodies that are immunoreactive to E. coli
antigens. This may be because cattle are frequently exposed to numerous bac-
teria, including E. coli. Alternatively, antibodies against P. haemolytica proteins
may be cross-reactive with E. coli antigens. Our studies with P. haemolytica
PomA have shown that antibodies against PomA are cross-reactive with E. coli
OmpA and vice versa (reference 28 and data not shown). As shown in Fig. 1,
antibodies in the serum used in this study recognized E. coli antigens of approx-
imately 28, 32, and 40 kDa. The immunoreactive bands at 32 and 40 kDa likely
correspond to the two different forms of the heat-modifiable E. coli OmpA. The
nature of the immunoreactive E. coli antigen of 28 kDa is unknown.
Antibodies against P. haemolytica ;45-kDa OMPs were purified from the
bovine hyperimmune serum by immunoaffinity (20). Briefly, P. haemolytica outer
membranes were purified as described previously (37), separated by preparative
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (14),
and transferred to nitrocellulose membranes (37). The region of the nitrocellu-
lose membrane containing ;45-kDa proteins was identified by comparison with
prestained molecular weight standards (Bio-Rad Laboratories, Richmond, Cal-
if.) on the membrane. The 45-kDa region of the nitrocellulose was excised and
incubated for 1 h with the bovine hyperimmune serum (1:25) in 0.01 M Tris-HCl
(pH 7.4)–0.2 M NaCl (TS), containing 0.05% gelatin and 0.05% Tween (TSGT).
Nitrocellulose strips were washed with TS, three times for 5 min each time.
Anti-45-kDa-protein antibodies bound to antigen on the nitrocellulose strips
were eluted as described elsewhere (20). The eluted antibodies were concen-
trated by using a Centriprep 10 concentrator (Amicon Inc., Beverly, Mass.).
These antibodies are referred to throughout this paper as anti-45-kDa antibod-
ies. Antibodies against at least three OMPs that migrate at ;45 kDa are present
in this preparation. However, the predominant antibodies in the preparation are
those against PlpE. When antibodies are affinity purified by the method we used,
contaminating antibodies are frequently present. We found antibodies against P.
haemolytica PomA, a heat-modifiable protein belonging to the OmpA family
(28), to be contaminants when the anti-45-kDa antibodies were purified by this
procedure. PomA migrates at ;30 and 38 kDa, and immunoreactive bands are
apparent in Western immunoblots that used the anti-45-kDa antibodies purified
in this study.
Gene cloning, DNA sequencing, site-directed mutagenesis, and sequence anal-
ysis. The plpE gene was cloned by screening a P. haemolytica expression library
(described above), according to the manufacturer’s instructions, with affinity-
purified anti-45-kDa antibodies. Additional DNA cloning was performed as
described previously (37). Plasmid inserts were progressively deleted from both
ends by using the Erase A Base kit (Promega Corp., Madison, Wis.), and
progressively smaller plasmid inserts were sequenced by using the universal and
reverse primers. Both DNA strands were sequenced. DNA sequencing was
performed at the Oklahoma State University Recombinant DNA/Protein Re-
source Facility, on an Applied Biosystems (Foster City, Calif.) model 373A
automated DNA sequencer. Site-directed mutagenesis was performed by using
the Gene Editor in vitro Mutagenesis System (Promega Corp.). Mutations were
confirmed by DNA sequence analysis. Sequences were analyzed with MacVec-
tor/Assemblylign software (Oxford Molecular Group, Inc., Campbell, Calif.).
The deduced amino acid sequence of PlpE was compared with other sequences
in GenBank by using BLAST 2.0 (1), and alignments were generated with
CLUSTALW 1.7 at the Baylor College of Medicine Search Launcher.
Antigen preparation and Western immunoblots. Whole-cell lysates were pre-
pared and Western immunoblots were performed as described previously (14,
37). Primary antibodies used for each Western immunoblot experiment are
described in Results. Alkaline phosphatase-conjugated mouse monoclonal, anti-
bovine immunoglobulin G antibody (Sigma Immunochemicals, St. Louis, Mo.)
(1:20,000 in TSGT) was used as the secondary antibody in Western immunoblots.
For Western immunoblots, bovine immune serum was absorbed with intact P.
haemolytica by using a modification of a previously described method (19).
Logarithmic-phase P. haemolytica cells, from 1 liter of culture (A600 of 0.5), were
pelleted by centrifugation, washed once in PBS, and resuspended in immune
serum diluted 1:100 in Tris-saline-nonfat dry milk (TSM) (10 mM Tris [pH 7.4],
0.9% [wt/vol] NaCl, 1% nonfat dried milk). Cells resuspended in serum were
incubated at 4°C for 3 h on a rocking platform. Following incubation, cells were
pelleted by centrifugation at 11,000 3 g. The supernatant was carefully removed
and stored at 220°C after the addition of sodium azide at 0.02%. Unabsorbed
immune serum was used as a control and was diluted 1:100 in TSM before use.
Serum absorptions with recombinant E. coli(pB4522) and nonrecombinant E.
coli(pBluescript SK2) were performed similarly except that stationary-phase
organisms were used.
[3H]palmitic acid labeling of bacterial lipoproteins. Labeling and analysis of
P. haemolytica, recombinant E. coli expressing PlpE, and nonrecombinant E. coli
were performed by using [9,10-3H]palmitic acid (Dupont, NEN, Boston, Mass.)
as described previously (14).
Complement-mediated killing assay. Serum from a calf with a low antibody
titer against P. haemolytica as determined by an enzyme-linked immunosorbent
assay was used as a complement source. The complement source serum was
depleted of any existing antibodies against P. haemolytica by incubation with
excess stationary-phase P. haemolytica at 4°C on a rocking platform for 1 h.
Before incubation with complement source serum, P. haemolytica cells were
washed once with cold PBS (4°C).
Serum from an OMP-vaccinated calf (described above) was used as the source
of antibodies. The antibody source serum was heat inactivated at 56°C for 30 min
and was used in two different forms. For the first form, anti-PlpE antibodies were
removed from the antibody source serum by absorption of the serum with
recombinant E. coli expressing PlpE. This process would also remove any anti-E.
coli antibodies that were present in the serum. For the second form, control
serum from which only anti-E. coli antibodies were removed was prepared by
absorption of the antibody source serum with nonrecombinant E. coli(pBlue-
script SK2). For absorbing sera to be used in complement killing assays, recom-
binant or nonrecombinant E. coli cells were grown overnight in 100 ml of Luria
broth (Life Technologies Inc., Grand Island, N.Y.) and harvested by centrifuga-
tion (11,000 3 g) at 4°C. Cells were washed once with PBS and resuspended in
2 ml of antibody source serum that had been diluted 1:1 with PBS. Cells and
serum were incubated on a rocking platform for 3 h at 4°C. After incubation, cells
were removed from serum by centrifugation. The process was repeated until the
serum absorbed with recombinant E. coli no longer recognized PlpE in a West-
ern immunoblot (data not shown).
The complement-mediated killing assay was developed by modifying the tech-
niques described by Chae et al. (5) and Murphy et al. (33). To ensure that the
assay was capable of detecting a change in the amount of bactericidal antibody,
numbers of bacteria and the concentration of complement were evaluated in
preliminary experiments (33). For complement-mediated killing assays, bacteria
were grown in BHI broth for 18 h at 37°C, on a rotary shaker (200 rpm). Cells
were washed once with PBS and resuspended in PBS to an A600 of 0.5. Com-
plement source serum (50 ml) and antibody source serum (form 1 or 2 described
above) (50 ml) were added to 150 ml of PBS. P. haemolytica cells (;9,000 to
18,000 CFU in 40 ml of PBS) were then added. Immediately after the addition of
P. haemolytica (t 5 0) and after incubation for 30 min in a 37°C water bath (t 5
30), 100-ml samples were removed and diluted 1:100 in PBS. Dilutions were
prepared and plated on BHI agar plates for determination of CFU. To monitor
the killing activity of the complement source serum alone, a control with only
complement source serum and no antibody source serum was evaluated in an
identical manner. We also determined that the heat-killed antibody source serum
alone had no killing activity (data not shown). Percent killing was calculated by
the following formula: {(CFUt50 2 CFUt530)/CFUt50} 3 100. Percent survival
was calculated as 100 2 (percent killing).
Statistical analysis. Within each experiment, complement-mediated killing
assays were done in triplicate for each antibody source serum and the comple-
ment source serum control. Additionally, three separate experiments were done
on different days. Statistically significant differences between percent killing by
different sera within experiments were determined by Student’s t test (2).
Nucleotide sequence accession number. The nucleotide sequence of P. hae-
molytica plpE has been deposited in GenBank under accession no. AF059036.
RESULTS
Cloning of plpE. To isolate a clone expressing the immuno-
genic 45-kDa protein, we screened a genomic library of P.
haemolytica S1 with anti-45-kDa antibodies that were affinity
purified from bovine immune serum. We isolated recombinant
lZAPII phage that reacted with the affinity-purified antibod-
ies. A recombinant plasmid containing a 4.5-kbp insert was
excised from one phage clone and transformed into E. coli
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XL1-Blue. We subcloned a 2.2-kbp fragment from this insert
into pBluescript SK(2) and named this plasmid pB4522. E.
coli(pB4522) expressed a 45-kDa protein that was recognized
by the affinity-purified antibodies and bovine immune serum
(Fig. 1a). We named this protein PlpE.
Surface exposure of PlpE. As mentioned earlier, we previ-
ously demonstrated the presence of an immunogenic 45-kDa
P. haemolytica protein that is surface exposed (36). To deter-
mine if PlpE expressed by the recombinant E. coli strain cor-
responds to the strongly immunogenic P. haemolytica surface
protein, we examined surface exposure of the protein on intact
P. haemolytica. Absorption of bovine immune serum with in-
tact P. haemolytica resulted in a loss of antibody reactivity on
Western immunoblots with rPlpE and a protein of the same Mr
in P. haemolytica whole-cell lysates (Fig. 1a and b), suggesting
that PlpE is surface exposed in P. haemolytica. Similarly, ab-
sorption of the same bovine immune sera with intact recom-
binant E. coli(pB4522) expressing PlpE resulted in a loss of
reactivity to rPlpE and to a 45-kDa protein in P. haemolytica
(Fig. 1c and d). These data suggest that PlpE is also exposed on
the surface of recombinant E. coli and that PlpE is the primary
45-kDa surface-exposed immunogen of P. haemolytica.
DNA sequence analysis of PlpE. DNA sequencing of the
cloned insert in pB4522 revealed an open reading frame of
1,068 nucleotides that begins with a GTG codon and encodes
a protein with a calculated molecular mass of 39.1 kDa (Fig. 2).
The deduced amino acid sequence contains a putative hydro-
phobic signal peptide followed by a consensus lipoprotein pro-
cessing site (LSAC) (Fig. 2). The calculated molecular mass of
the putative mature form of PlpE is 37.03 kDa. The N-terminal
region of the mature PlpE contains eight imperfect copies of a
repeated hexapeptide (Fig. 2) that are encoded by 18-nucleo-
tide repeats (Fig. 3). The hexapeptide repeat is predicted to
form a large hydrophilic domain in PlpE (Fig. 4). PlpE also has
numerous other hydrophilic domains that correspond to re-
gions with a high probability of being surface exposed (Fig. 4).
A search of GenBank sequences and subsequent sequence
alignments revealed that the deduced amino acid sequence of
PlpE has 18% identity and 32% similarity to an outer mem-
brane lipoprotein (OmlA) produced by Actinobacillus pleuro-
FIG. 1. Western immunoblots demonstrating expression and surface expo-
sure of PlpE in P. haemolytica and recombinant E. coli. Lanes contain whole-cell
lysates of P. haemolytica (lanes 1), E. coli(pB4522) (lanes 2), and nonrecombi-
nant E. coli(pBluescript SK2) (lanes 3). Blots were probed with various forms of
bovine immune serum from a calf vaccinated with P. haemolytica OMPs: bovine
immune serum (a), immune serum absorbed with P. haemolytica (b), immune
serum absorbed with E. coli(pBluescript SK2) (c), and immune serum absorbed
with E. coli(pB4522) (d). The arrows designate the 45-kDa band corresponding
to PlpE. The immunoreactive E. coli antigens are discussed in the description of
bovine immune sera in Materials and Methods.
FIG. 2. Nucleotide sequence of plpE and deduced amino acid sequence of
PlpE. Bases 59 of the gene and corresponding to E. coli consensus 235 and 210
sequences and ribosome binding sites (RBS) are underlined. A consensus li-
poprotein processing site is underlined with a dashed line. Cleavage of the signal
peptide (residues 1 to 18) would occur after the alanine residue at position 18.
The eight hydrophilic hexapeptide repeats in the amino-terminal region of PlpE
are doubly underlined.
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pneumoniae serotype 1 and 20% identity and 35% similarity to
the OmlA protein from A. pleuropneumoniae serotype 5 (data
not shown). Although both of those proteins lack the hexapep-
tide repeat mentioned above, they contain regularly spaced PK
and PQ repeats in the same region (4, 17, 23).
Site-directed mutagenesis of the GTG start codon. To verify
that GTG functions as a translational start codon for PlpE, we
performed site-directed mutagenesis and converted the codon
to GGG. Western immunoblots of whole-cell lysates from the
wild-type and mutant E. coli(pB4522) strains, probed with anti-
45-kDa antibodies, revealed that the mutant no longer pro-
duced a 45-kDa immunoreactive protein, suggesting that GTG
functions as the translational start codon (Fig. 5).
Lipid modification of PlpE. Because the deduced amino acid
sequence contained a consensus lipoprotein processing site, we
examined P. haemolytica and E. coli(pB4522) for the presence
of 45-kDa lipid-modified proteins. P. haemolytica, E. coli
(pB4522), and nonrecombinant E. coli(pBluescript SK2) were
grown in the presence of [3H]palmitic acid. A 45-kDa, 3H-
labeled lipoprotein is present in whole-cell lysates of P. hae-
molytica and E. coli(pB4522) but absent from the nonrecom-
binant E. coli strain (Fig. 6).
Conservation of PlpE among serotypes of P. haemolytica. To
determine if PlpE is expressed by other P. haemolytica sero-
types, we examined whole-cell lysates of P. haemolytica sero-
types 1, 2, 5, 6, 7, 8, 9, 11, 12, 13, and 14 and an untypeable
strain of P. haemolytica, by Western immunoblot analysis, for
reactivity with the anti-45-kDa antibodies (Fig. 7). The anti-
bodies reacted strongly with a 45-kDa protein in serotypes 1, 5,
6, 7, 8, 12, and 14; a 38-kDa protein in serotype 2; a 36-kDa
protein in serotype 13; and an ;80-kDa protein in serotype 9
and the untypeable strain. The antibodies reacted weakly with
a unique band at 43 kDa in serotype 9. The antibodies did not
react strongly with a protein in the serotype 11 strain.
Role of anti-PlpE antibodies in complement-mediated kill-
ing of P. haemolytica. We sought to determine if anti-PlpE
antibodies contribute to complement-mediated killing of P.
haemolytica. Since we had observed that E. coli(pB4522) has
the capacity to remove anti-PlpE antibodies from bovine se-
rum (Fig. 1d), we used the recombinant strain to remove those
antibodies from immune serum of a calf that was vaccinated
with P. haemolytica OMPs. We then compared rates of com-
plement-mediated killing of P. haemolytica using, as an anti-
body source, bovine immune serum or immune serum depleted
of anti-PlpE antibodies. As shown in Fig. 8, immune serum
that was depleted of anti-PlpE antibodies caused less killing of
P. haemolytica than did immune serum that was not depleted
of those antibodies. For each of three separate experiments,
the difference in killing activity between the two sera was
statistically significant (P , 0.003).
DISCUSSION
As mentioned earlier, numerous studies have indicated that
P. haemolytica OMPs are important in eliciting protective im-
munity in cattle and that antibody responses of cattle to P.
haemolytica OMPs correlate with resistance to experimental P.
haemolytica challenge. However, not all antibody responses to
individual antigens contribute significantly to host defense, and
some may actually be detrimental to certain defense mecha-
nisms (30, 38, 49). Therefore, one of our goals is to identify and
FIG. 3. Repeated nucleotide sequences encoding the eight hexapeptide re-
peats within the N-terminal region of PlpE. The consensus nucleotide and
peptide repeats are shown. Nucleotides within repeats that match the consensus
are indicated with a dash, and those that differ from the consensus are indicated
with lowercase letters. Numbers shown correspond to amino acid residues in Fig.
2 and 4.
FIG. 4. Hydrophilicity plot of the deduced amino acid sequence of PlpE. The signal peptide and the hydrophilic hexapeptide repeats are indicated. Positive values
represent hydrophilic regions. The plot was generated in MacVector (Oxford Molecular Group, Inc.) by using the Kyte-Doolittle algorithm with a window size of 7.
FIG. 5. Western immunoblot demonstrating the effect of mutagenesis of the
GTG codon on production of PlpE. The blot was probed with anti-45-kDa
antibodies. Lanes: 1, E. coli(pB4522) with GTG and expressing PlpE; 2, E.
coli(pB4522) in which GTG was changed to GGG by site-directed mutagenesis.
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characterize individual P. haemolytica OMPs that elicit anti-
bodies which function in host immune mechanisms.
In our previous work, we observed an immunoreactive band
at 45 kDa on Western immunoblots of P. haemolytica OMPs
that were probed with three different sera from cattle resistant
to P. haemolytica infection (36). Those studies also revealed
the 45-kDa antigen to be a surface-exposed protein. Here, we
present genetic and immunologic characterization of a P. hae-
molytica 45-kDa surface-exposed lipoprotein (PlpE) and dem-
onstrate that bovine antibodies against PlpE contribute to
complement-mediated killing of P. haemolytica. The results of
our study demonstrate that PlpE is the major P. haemolytica
antigen responsible for the significant, immunoreactive band at
45 kDa in Western immunoblots probed with immune sera
from cattle.
Our analysis of the deduced amino sequence of PlpE re-
vealed several interesting features. Although PlpE migrates at
an Mr of 45 kDa on SDS-polyacrylamide gels, the calculated
molecular mass of the putative mature form of PlpE is ;37
kDa. This discrepancy may possibly be a result of the high
proline content of PlpE (;6%). Proline is a turn-inducing
amino acid residue that often causes proteins to migrate slower
on SDS-PAGE (39). The deduced amino acid sequence of
PlpE also contains a typical signal peptide, followed by a con-
sensus lipoprotein processing site, and in this study we dem-
onstrated lipid modification of rPlpE. Another interesting fea-
ture of plpE is that GUG functions as the translational start
codon. GUG, AUG, and UUG are in the group of class I
initiation codons that support efficient translation (48). In E.
coli, the intrinsic activity of GUG is 12 to 15% that of AUG
(41). About 8% of known genes from E. coli and other bacteria
use GUG as the start codon (43). The aroA gene of Pasteurella
multocida appears to use GUG as an initiation codon (21).
However, to our knowledge plpE is the first example of a P.
haemolytica gene with GUG as a start codon.
Protein sequence similarities are present between the
QAQNAP repeats in PlpE and a newly identified peptide re-
peat (NAP) in some forms of the polymorphic merozoite sur-
face protein 2 (MSP2) from Plasmodium falciparum (22). The
NAP repeats, like the QAQNAP repeats in PlpE, occur near
the amino terminus of MSP2, and similarities between PlpE
and MSP2 include glycines and serines on the amino-terminal
side of the repeat regions. Hydrophilicity plots of PlpE and this
form of MSP2 are also similar from the amino terminus, ex-
tending across the repeated region (data not shown). DNA
sequence identity exists as well between the consensus nucle-
otide sequence encoding the NAP repeat unit of MSP2 (AA
TGCTCCA) and the consensus nucleotides encoding the cor-
responding region in the PlpE hexapeptide repeat (AATGCT
CCT). In mouse immunization experiments with synthetic
peptides and a rMSP2, an immunodominant T-cell determi-
nant was mapped to a region spanning the NAP sequence (42).
More detailed immunological studies are required to deter-
mine if such a role may exist for the hexapeptide repeat in
PlpE.
Within the hexapeptide repeat of PlpE, codon sequences are
generally conserved for each amino acid position, and unusual
codons for P. haemolytica are also conserved in this region.
Seven of the eight codons for the first glutamine of each repeat
are CAG, whereas for the second glutamine, six of six codons
are CAA. In P. haemolytica, CAA is the preferred codon for
glutamine (26) and is reflective of the high moles percent A1T
content (;60%) of P. haemolytica chromosomal DNA. For the
first alanine in the repeat, six of six codons are GCA, whereas
for the second alanine, five of seven codons are GCT. Simi-
larly, all asparagines are encoded by AAT, and all prolines are
encoded by CCT. The relative synonymous codon usage in P.
FIG. 6. Autoradiograph of an SDS-polyacrylamide gel of [3H]palmitate-la-
beled total cellular proteins. Lanes: 1, P. haemolytica; 2, E. coli(pB4522); 3, E.
coli(pBluescript SK2).
FIG. 7. Western immunoblot of whole-cell lysates of P. haemolytica serotypes
1, 2, 5, 6, 7, 8, 9, 11, 12, 13, and 14 and an untypeable strain, probed with
anti-45-kDa antibodies. The lane numbers represent the serotypes, with UT
representing the untypeable strain. Weakly reactive bands that are common in all
lanes and weakly reactive bands at 45 kDa in lanes 2, 11, and 13 are likely due
to nonspecific antibodies that were eluted with the anti-PlpE antibodies during
the affinity purification process (see Materials and Methods). The immunoblot
was performed twice with different whole-cell lysate preparations for each strain
and yielded similar results each time.
FIG. 8. Complement-mediated killing activity of anti-OMP bovine immune
serum with and without anti-PlpE antibodies. Sera used as the source of anti-
bodies were bovine immune serum absorbed with E. coli(pB4522) (A), bovine
immune serum absorbed with E. coli(pBluescript SK2) (B), and complement
source alone (C). Values greater than 100% represent growth. Data shown are
the means and standard deviations (error bars) of three replicates from a single
experiment and are representative of three separate experiments. The differ-
ences between the means for the experiments represented by bars A and B are
statistically significant (P , 0.003).
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haemolytica for CCT was calculated by Lo et al. (26) to be
slightly lower than that for CCA. Our recent analyses with a
larger number of P. haemolytica genes revealed similar results
(31). These data suggest that expansion of the hexapeptide
repeat may have occurred by duplication of one or more of the
18 nucleotide repeats.
Additional amino acid sequence alignments revealed that
the A. pleuropneumoniae OmlA lipoproteins are similar to
PlpE over its entire sequence. A. pleuropneumoniae is a patho-
gen of pigs that causes a fibrinous pleuropneumonia very sim-
ilar to that caused by P. haemolytica in cattle. Vaccination of
pigs with protein aggregates containing rOmlA, cloned from A.
pleuropneumoniae serotype 1, significantly reduced lung dam-
age and death of pigs upon subsequent experimental challenge
with a homologous A. pleuropneumoniae serotype (17). Simi-
larly, vaccination of pigs with gel-purified rOmlA, cloned from
A. pleuropneumoniae serotype 5a, significantly lowered mortal-
ity upon challenge with a serotype 5a strain (4).
The OmlA proteins from different A. pleuropneumoniae se-
rotypes may be more antigenically heterogeneous than are the
PlpE proteins from the different P. haemolytica serotypes. A.
pleuropneumoniae serotypes 1, 5, and 7 are the most common
in North America. Sera from pigs vaccinated with rOmlA (se-
rotype 1) failed to recognize proteins in 6 of 13 A. pleuropneu-
moniae serotypes and only weakly recognized a protein in 3 of
those serotypes (17). Similarly, rabbit antisera against rOmlA
from serotype 5a recognized a protein only in serotypes 5a, 5b,
and 10 (4, 23). These data suggest that OmlA proteins from a
single serotype are unlikely to be cross-protective for heterol-
ogous serotypes. Indeed, one A. pleuropneumoniae vaccine cur-
rently under evaluation includes, among other antigens, rOmlA
proteins from both serotypes 1 and 5 (24).
In contrast, our Western immunoblots revealed that anti-45-
kDa antibodies, affinity purified from bovine immune sera,
recognize a protein in all but one P. haemolytica serotype
(serotype 11). P. haemolytica serotypes 1 and 6 are most fre-
quently isolated from the lungs of pneumonic cattle in the
United States. Thus, PlpE may have potential for being a
significant cross-protective antigen for those serotypes. Several
P. haemolytica serotypes possess immunoreactive antigens with
Mrs different from that of PlpE (Fig. 7), including serotypes 2
(;38 kDa) and 9 (;80 kDa) and the untypeable strain (;80
kDa). Although purely speculative at this time, it is possible
that variation in the number of hexapeptide repeats could
account for these differences in Mrs. Alternatively, as discussed
above, different percentages of proline residues in the proteins
from different serotypes could alter the mobility of these pro-
teins. Significant differences in P. haemolytica serotype 1 and
serotype 9 OMPs were also suggested by the results of a recent
vaccine trial. Vaccination of calves with OMPs purified from a
serotype 9 strain did not provide significant protection from
experimental challenge with a serotype 1 strain (29). Future
studies will be necessary to evaluate the capacity of PlpE to
enhance protection of cattle against experimental challenge
with homologous and heterologous serotypes of P. haemo-
lytica.
Results of the complement-mediated killing assays demon-
strate that anti-PlpE antibodies contribute to this mechanism
of bovine defense, one that is believed to be important in
protection against P. haemolytica pneumonia. Immune serum
that was depleted of anti-PlpE antibodies also caused signifi-
cant amounts of killing, ;75% under these assay conditions.
These results suggest that antibodies against other surface an-
tigens also contribute to complement-mediated killing. Ab-
sorption of bovine immune serum with intact P. haemolytica
results in the loss or reduction of immunoreactivity in Western
blots to numerous antigens (Fig. 1a and b), any of which may
bind antibodies that effect complement-mediated killing. Iden-
tification of these antigens and elucidation of the role of anti-
bodies directed against them in bovine immune mechanisms
are currently major focuses of our research.
Control complement-mediated killing assays with only com-
plement source and no antibody source indicated that comple-
ment alone failed to kill P. haemolytica, suggesting that com-
plement activation strictly through the alternative pathway
does not play a significant role in the killing of the organism.
These data are in agreement with those of previous studies
which demonstrated that only activation of the complement
cascade through the classical pathway is important in killing P.
haemolytica (3, 27).
Studies in our laboratory to evaluate the role of anti-PlpE
antibodies in other mechanisms of host defense, such as neu-
trophil phagocytosis and killing, and to identify additional
OMPs that may be important in protective immunity against P.
haemolytica are under way. The addition of PlpE and other
OMPs which elicit protective antibodies to vaccines containing
leukotoxin may provide significant protection against pneumo-
nic pasteurellosis.
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